Sangamo Therapeutics (SGMO) Misses Q4 EPS by 8c

Sangamo Therapeutics (NASDAQ: SGMO) reported Q4 EPS of ($0.34), $0.08 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $2.04 million versus the consensus estimate of $8.11 million.

For earnings history and earnings-related data on Sangamo Therapeutics (SGMO) click here.

You May Also Be Interested In

• Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
• S&P Global completes sale of energy software portfolio to SLB
• Medtronic jumps on earnings beat and raised guidance